Adnkronos The Innovative Medicines Fund (FFI) has arbitrarily chosen three years as the timeframe for the inclusion of the drugs in question. It's clear that, in some cases, this arbitrary timeframe effectively reflects the drug's value and pathway, within the context of the disease and the patient. However, in other cases, more time is needed to better understand the full value of this type of therapy.
Therefore, extending the time can be helpful, especially given the regional variability we are currently witnessing, to fully benefit from this type of therapy." These are the words of Rossana Berardi, president-elect of the Italian Association of Medical Oncology (AIOM), speaking at the 28th National Congress of the Italian Association of Medical Oncology (AIOM), scheduled for November 13-15 in Rome.
https://www.youtube.com/watch?v=4g0GFCWapUQ